ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 186 (planned)
- Started
- Jun 15, 2022
- Main results expected
- Jun 30, 2027
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.
Measured over: 9 months
the safety and tolerability of ADG126 at escalating dose level in combination with pembrolizumab in adults with advanced metastatic solid tumors
Measured over: 9 months
Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimens
Measured over: 9 months
Maximum tolerated dose (MTD) and/or RP2D for ADG126 with Trifluridine/Tipiracil-Bevacizumab
Measured over: 6 months
Access the preliminary antitumor activity of ADG126 with Pembrolizumab in combination standard of care
Measured over: 6 months
Access and characterize the optimal dose based on safety and efficacy parameters
Measured over: 9 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05405595 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC